Perspective Therapeutics (Perspective Therapeutics) Risk Assessment

View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Perspective Therapeutics is: No Data: Cannot be evaluated.

Competitive Comparison of Perspective Therapeutics's Risk Assessment

For the Medical Devices subindustry, Perspective Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perspective Therapeutics's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Risk Assessment falls into.

Perspective Therapeutics (AMEX:CATX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Perspective Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Perspective Therapeutics (Perspective Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

AAJ:Germany

Address

350 Hills Street, Suite 106, Richland, WA, USA, 99354

Website

https://www.perspectivetherapeutics.com

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.

Executives

Williamson Robert F Iii	director	140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann	officer: Chief Medical Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt	officer: Chief Financial Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor	director, officer: CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin	officer: Controller/Prin Fin&Acct Offic	350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale	director	8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick	director	9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann	director	3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon	officer: VP of Sales & Marketing	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline	officer: Dir. of Operations, Secretary	350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter	officer: VP of Human Resources	350 HILLS STREET SUITE 106, RICHLAND WA 99354